Board of Directors

   Jean-Philippe Tripet, CFA

Mr. Jean-Philippe Tripet is founder and Managing Partner of Aravis Venture, an internationally active venture fund focused on biotech investments. Jean-Philippe Tripet has over 15 years experience as portfolio manager and financial analyst. He has a degree in business administration from the University of Geneva, did graduate studies in San Diego (USA) and is a Chartered Financial Analyst.

In 1994 Jean-Philippe Tripet co-founded the LO Fund that became one of the most successful healthcare funds in Europe under his leadership. He has supervised over 70 private biotech investments. Until 2001, he was a Senior Executive Vice-President and member of Group Management at Lombard Odier & Cie, Geneva.

He founded Aravis Venture I in 2002.

Since 1994 Jean-Philippe Tripet has participated actively in the launch and financing of many successful start-up companies such as Modex, NovImmune, Cytos, Genedata, Esbatech and Glycart. He is also Chairman of the board of directors of Evolva and Athelas, Vice Chairman of Symetis, and a director and Omeros.

     
 

Chu Swee Yeok

Ms Chu joined EDBI Pte Ltd, EDB’s dedicated investment arm, as its Chief Executive Officer in late 2008, bringing with her over 20 years of extensive experience in equity investments and a track record in start-up, growth and late-stage ventures, strategic planning, business and technology development.  She is responsible for repositioning EDBI as an active value-adding investor supporting the fast growing innovative Biomedical Sciences, Smart & Sustainable Technology and Information & Communication Technology sectors, as well as key strategic industry clusters that EDB is developing.

Prior to EDBI, from 2004 Ms Chu was CEO of Bio*One Capital Pte Ltd.  Under her leadership, Bio*One became a globally recognised and reputable investment fund manager with a portfolio of over 50 therapeutic, medical technology and service companies worldwide and in Singapore.

Previously, Ms Chu held major positions at EDB and Agency for Science & Technology Research where she played a pioneering role in developing and implementing industry, research and commercialisation strategies leading to the growth of the biomedical sector as a major pillar today of Singapore’s economy.  Starting in 1990 she was instrumental in establishing several of EDB’s venture funds and in providing oversight of their management.

Ms Chu serves on the board of EDBI, Singapore-Suzhou Township Development and Alexandra Health Endowment Fund.
 

     
  Clemens Doppler, PhD

Dr Doppler is a Managing Partner at Heidelberg Capital Asset Management GmbH. Prior to joining Heidelberg Capital in 2008, he was a director at 3i since 2000 and has 10 years of international business experience in the pharma and biotech industries. He held senior position at Boehringer Mannheim (now Roche) and was in the management team of Swiss Biotech company ANAWA Laboratories AG, which was successfully sold in 1997 to Phoenix International Life Science (now MDS Inc.). As well as serving on various boards, Dr Doppler is a member of the German biotech analyst association DVFA. He is also a fellow of the German Cancer Research Centre. Dr Doppler holds degrees in marketing and economics and a MSc and Ph.D. in molecular biology, chemistry and microbiology from the University of Heidelberg.